Portal de Periódicos da CAPES

Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry

2012; European Association of Percutaneous Cardiovascular Interventions; Volume: 8; Issue: 8 Linguagem: Inglês

10.4244/eijv8i8a147

1969-6213

Darren Mylotte, Brahim Meftout, Anouska Moynagh, Beatriz Vaquerizo, Olivier Darremont, Marc Silvestri, Yves Louvard, Jean-Louis Leymarie, Marie‐Claude Morice, Thierry Lefévre, Philippe Garot,

Cardiac Valve Diseases and Treatments

Limited long-term data are available to support drug-eluting stent (DES) unprotected left main (LM) intervention. We sought to evaluate long-term outcomes of LM intervention with paclitaxel-eluting stents.In this prospective multicentre registry, 291 patients with unprotected LM stenosis underwent percutaneous revascularisation with the TAXUS® Express® stent, using a consistent technical approach for both ostial/shaft and bifurcation lesions (provisional side branch stenting). At five years (n=263), the cumulative incidence of major adverse cardiac events (MACE) and cardiac death were 23.6% and 12.5%, respectively. Myocardial infarction (MI) occurred in 16 patients (6.1%), definite stent thrombosis in 0.4%, and target lesion revascularisation (TLR) was required in 10.3%. Patients with distal LM lesions requiring two-stent procedures had increased MACE compared with those with single-stent interventions (34.1% vs. 17.8%, p=0.009). This was primarily driven by an increased incidence of cardiac death (18.2% vs. 8.5%, p=0.05). Diabetes was associated with increased TLR and was an independent predictor of MACE at five years (odds ratio [OR] 2.10, 95% confidence interval [CI] 1.10-3.99, p=0.02).This study confirms the long-term safety and efficacy of the TAXUS® DES in unprotected LM stenting. Diabetes and the need for a second stent in distal LM interventions were associated with an increased risk of adverse outcomes.